No Data
Atai Life Sciences Chief Scientific Officer Details VLS-01 Trial Success - ICYMI | NASDAQ:ATAI, ETR:9VC
Maxim Group Maintains ATAI Life Sciences(ATAI.US) With Buy Rating, Maintains Target Price $6
Positive Outlook for ATAI Life Sciences Amidst Upcoming Clinical Trials and Strategic Collaborations
CCORF Maintains ATAI Life Sciences(ATAI.US) With Buy Rating, Maintains Target Price $11
Buy Rating Affirmed for ATAI Life Sciences With Promising Clinical Outlook and Strategic Pipeline Reprioritization
Lykos Laying off 75% of Workforce Following FDA Rejection of Psychedelic Drug for PTSD